A retrospective review of therapeutic failures of miconazole in three patients is presented. Miconazole, a new imidazole derivative, is a broad-spectrum antifungal agent purportedly effective topically, orally, and parenterally against a number of species of fungi. Three patients with the following culturally proven deep fungal infections were treated with miconazole: (i) destructive arthritis (Sporothrix schenckii), (ii) meningoencephalitis ( Cryptococcus neoformans), and (iii) disseminated aspergillosis (Aspergillus fumigatus). All the organisms were susceptible in vitro to 1.56 ,tg or less of miconazole per ml using a broth dilution technique.
Miconazole, a membrane-active imidazole derivative, has been shown to be inhibitory in vitro against dermatophytes, a variety of yeastlike organisms including Cryptococcus neoformans and Candida species, as well as dimorphic fungi such as Blastomyces dermatitidis, Histoplasma capsulatum, and Coccidioides immitis. It is usually active in concentrations of <1 .tg/ml (6) .
The in vivo systemic efficacy of the drug against infections due to C. immitis has been demonstrated in experimental animals and confirmed in humans by other investigators (2, 3, 5) .
A total of three patients with deep mycotic infections were treated with miconazole at the Medical College of Virginia Hospitals (MCV). Our experience with this drug is the subject of this report.
(This paper was presented at the 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, N.Y., October 1977j) MATERIALS 
AND METHODS
The diagnosis of a deep mycotic infection was made by recovery of a pathogenic fungus from tissue (patient 1, synovium and joint fluid; patient 3, subcutaneous abscess) and cerebrospinal fluid (CSF; patient 2). Sus- patient was begun on amphotericin B; less than 1 month after completing therapy, a relapse occurred. Thus he was treated with the combination of amphotericin B and flucytosine. When this treatment failed, miconazole was employed. The MIC and minimum fungicidal concentration (MFC) of miconazole were both 0.05 ,g/ml against this isolate. Serum and CSF were assayed for miconazole. Two hours after a standard dose, 2.54 ,tg of miconazole per ml was detected in the single serum sample. Three lumbar CSF samples were obtained from 1.5 to 6 h following a similar dose. Miconazole was detected in none of these ( Table 1) . The patient's disease continued to progress, and his course was complicated by obstructive hydrocephalus requiring placement of a ventriculoperitoneal shunt for decompression. The findings of repeatedly positive India ink preparations, persistent growth of C. neoformans from ventricular CSF, and high cryptococcal antigen titers indicated suboptimal therapy. A Rickham reservoir was thus employed in the lateral ventricle opposite the ventriculoperitoneal shunt, and miconazole was given intraventricularly in a dosage of 15 mg every 2 to 3 days while continuing the intravenous infusion. Prior to each intraventricular dose through the Rickham reservoir, the mechanical valve of the ventriculoperitoneal shunt was closed, thereby preventing immediate drainage of miconazole into the peritoneal cavity. The patient tolerated the closure for approximately 6 h. On two occasions this program produced ventricular fluid levels in excess of 120 tig/ml when samples were obtained 5 min after instillation. Ventricular fluid was also assayed for miconazole immediately prior to each intraventricular dose and from 1 to 7.5 h after an intravenous dose. Less than 0.5 jg of the drug per ml was present in each sample ( Table   1 ). The organism was not eradicated. Significant adverse effects included phlebitis and moderately severe nausea and vomiting (especially after intraventricular treatment). Ultimately, intraventricular combined with intravenous amphotericin B was required for sterilization of the CSF. However, the patient continued to deteriorate and died in spite of this therapy. Numerous organisms compatible with C. neoformans were seen in postmortem sections of the brain and meninges.
Patient 3. A 9-year-old white male with known chronic granulomatous disease of childhood and a history of recurrent otolaryngeal and cutaneous infections was admitted to MCV because of fever, nonproductive cough, and dyspnea of 1 to 2 months' duration. Aspergillus fumigatus had been isolated repeatedly from sputum as well as from two subcutaneous abscesses. Physical examination revealed a thin, tachypneic, chronically ill-appearing white male. Examination of the chest showed scattered rales and rhonchi. A fluctuant subcutaneous paravertebral mass (2 by 3 cm) was evident at the level of thoracic vertebrae eight and nine. Chest roentgenogram showed destructive lesions of several ribs compatible with osteomyelitis, but no pulmonary parenchymal abnormality. The patient was treated with miconazole (Fig. 2) Preliminary studies indicating the therapeutic efficacy of miconazole in coccidioidomycosis and candidiasis in laboratory animals have been done (3, 6) . Using appropriate animal models, confirmatory data in other systemic fungal infections are needed. In addition, more pharmacokinetic information in human subjects is required before miconazole can be adequately evaluated in the treatment of the deep mycoses.
The therapeutic effects of miconazole were studied in three patients. The organism isolated from each individual was susceptible to miconazole in vitro. Dosages used in all three were the maximum recommended by the drug manufacturer at the time of the study.
The findings lead to these conclusions. 
